ABSTRACT
Vigorous non-pharmaceutical interventions have largely suppressed the COVID-19 outbreak in Wuhan, China. We extended the susceptible-exposed-infectious-recovered model to study the transmission dynamics and evaluate the impact of interventions using 32,583 laboratory-confirmed cases from December 8, 2019 till March 8, 2020, accounting for presymptomatic infectiousness, and time-varying ascertainment rates, transmission rates, and population movements. The effective reproduction number R0 dropped from 3.54 (95% credible interval: 3.41-3.66) in the early outbreak to 0.27 (0.23-0.32) after full-scale multi-pronged interventions. By projection, the interventions reduced the total infections in Wuhan by 96.1% till March 8. Furthermore, we estimated that 87% infections (lower bound: 53%) were unascertained, potentially including asymptomatic and mild-symptomatic cases. The probability of resurgence was 0.33 and 0.06 based on models with 87% and 53% infections unascertained, respectively, assuming all interventions were lifted after 14 days of no ascertained infections. These results provide important implications for continuing surveillance and interventions to eventually contain the outbreak.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partly supported by the Fundamental Research Funds for the Central Universities (2019kfyXMBZ015), the 111 Project (X.H., S.C., D.W., C.W., T.W.). X.L. is supported by Harvard University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data were daily incidences of the COVID-19 epidemic without individual level data or sample of human subjects.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be released once granted by the authorities.
